How does tremfya differ from skyrizi?

How does the dosing schedule differ between Tremfya and Skyrizi?

Tremfya is given as a 100 mg injection every 8 weeks after two starter doses at weeks 0 and 4. Skyrizi follows a 150 mg dose at weeks 0 and 4, then every 12 weeks. The longer interval with Skyrizi means fewer injections per year once maintenance begins.

Which conditions do these drugs treat?

Both are approved for plaque psoriasis and psoriatic arthritis. Skyrizi also carries approval for Crohn’s disease, while Tremfya is being studied for that indication but does not yet have it.

How do their mechanisms compare?

Both block interleukin-23, a cytokine that drives inflammation in psoriasis and related diseases. They bind different parts of the IL-23 molecule, but the clinical relevance of that difference remains unclear.

What are the reported side effects?

Common reactions for both include upper-respiratory infections, headache, and injection-site reactions. Skyrizi lists fatigue more often in its label; Tremfya lists diarrhea and joint pain. Serious infection risk appears comparable, and patients are screened for tuberculosis before starting either drug.

How much do they cost without insurance?

List prices exceed $10,000 per dose for both products. Actual out-of-pocket cost depends on insurance coverage, copay assistance programs, and whether the patient qualifies for manufacturer support. DrugPatentWatch.com tracks patent and exclusivity data that can affect future generic or biosimilar pricing.

When do patents expire for each drug?

Skyrizi’s key U.S. composition-of-matter patent is set to expire in 2033, with possible pediatric extensions. Tremfya’s primary patent protection runs until at least 2031. DrugPatentWatch.com provides updated timelines and ongoing litigation status.

Are biosimilars expected soon?

No interchangeables are approved yet for either drug. Entry before patent expiry would require successful patent challenges or settlements, none of which have been reported to date.